Body and Cancer: a randomised phase III study in cancer patients undergoing chemotherapy - a supervised group exercise intervention versus standard care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN05322922

Enrollment

250

Registered

2007-08-13

Start date

2003-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncological and haematological cancer patients undergoing chemotherapy Cancer Malignant neoplasm without specification of site

Interventions

Cancer patients will be recruited from the Copenhagen University Hospital, Department of Oncology, Department of Haematology and from The Herlev Hospital, Department of Oncology. After informed cons

Eligibility

Inclusion criteria

Inclusion criteria: 1. World Health Organization (WHO) performance stage score zero to one 2. A diagnosis of cancer (one month previously), admitted to hospital for out-patient chemotherapy 3. Received at least one series of chemotherapy 4. Previously undergone surgery and/or radiotherapy 5. Age 18 to 65 years inclusive 6. Residence in the Greater Copenhagen Council 7. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Brain metastases 2. Bone metastases 3. Thrombocytopenia 4. Cardiovascular symptoms-cardial insufficiencies 5. No recent myocardial infarct 6. Normal blood pressure

Design outcomes

Primary

Measure	Time frame
Fatigue measure: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), measured at baseline, after six weeks and after three months.	—

Secondary

Measure	Time frame
1. Improvement in muscular strength, aerobic fitness measured using One Repetition Maximum (1RM), Maximal oxygen uptake (VO2max), measured at baseline and after six weeks 2. Improvement in quality of life measured using QLQ-C30, Functional Assessment Cancer Therapy-Anaemia (FACT-An), measured at baseline, after six weeks and after three months 3. Improvement in general well-being measured using Medical Outcomes Study 36-item Short Form (MOS SF-36), measured at baseline, after six weeks and after three months 4. Reduction in anxiety and depression measured using Hospital Anxiety and Depression Scale (HADS), measured at baseline, after six weeks and after three months 5. Physical activity level I - IV measured using the Saltin Scale, measured at baseline, after six weeks and after three months	—

Measure

Time frame

1. Improvement in muscular strength, aerobic fitness measured using One Repetition Maximum (1RM), Maximal oxygen uptake (VO2max), measured at baseline and after six weeks 2. Improvement in quality of life measured using QLQ-C30, Functional Assessment Cancer Therapy-Anaemia (FACT-An), measured at baseline, after six weeks and after three months 3. Improvement in general well-being measured using Medical Outcomes Study 36-item Short Form (MOS SF-36), measured at baseline, after six weeks and after three months 4. Reduction in anxiety and depression measured using Hospital Anxiety and Depression Scale (HADS), measured at baseline, after six weeks and after three months 5. Physical activity level I - IV measured using the Saltin Scale, measured at baseline, after six weeks and after three months

—

Countries

Denmark

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 2, 2026